Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 16, 2024 | May 16, 2024 |
| Travere Therapeutics, Inc.RTRX · Entity 1562 | Chief Operating Officer | May 15, 2019 | May 17, 2019 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director · President and CEO | October 10, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 16, 2024 · Filed May 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,365 |
Reported balance
After 2024-05-16 transaction · row 1
1 source rowRow 1 · 2024-05-16 · Grant · Acquired 7,693 · Balance 49,365 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
Travere Therapeutics, Inc.
Report date May 15, 2019 · Filed May 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,988 |
Ending reported balance
After 2019-05-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-15 · Sale · Disposed 984 · Balance 27,972 F1: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.67 to $17.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 2 · 2019-05-16 · Sale · Disposed 984 · Balance 26,988 F1: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.67 to $17.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
ZEVRA THERAPEUTICS, INC.
Report date October 10, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 417,225 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-10 · Exercise / conversion · Acquired 50,000 · Balance 437,225 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-10-12 · Sale · Disposed 20,000 · Balance 417,225 F2: Adoption date of referenced 10b5-1(c) plan is: 03-25-2026 F3: This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 50,000 |
Reported balance
After 2026-10-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-10 · Exercise / conversion · Disposed 50,000 · Balance 50,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4: 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: Adoption date of referenced 10b5-1(c) plan is: 03-25-2026
F3: This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-11-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-24 · Grant · Acquired 75,000 · Balance 600,000 F1: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested. Row 2 · 2021-11-24 · Other · Disposed 600,000 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F4: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2029-09-15 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 250,000 · Balance 0 F7: $1.85 plus two CVRs per share underlying the stock option. F5: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2030-03-17 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-24 · Disposition to issuer · Disposed 200,000 · Balance 0 F8: $6.11 plus two CVRs per share underlying the stock option. F5: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F3: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F4: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F5: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F7: $1.85 plus two CVRs per share underlying the stock option.
F8: $6.11 plus two CVRs per share underlying the stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 20,000 | $11.25 | $224,948.00 |
DisclosureSEC source: 0001434647-26-000075 · wk-form4_1791923065.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 417,225 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-25-2026 F3 · price: This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 10, 2026 Filed Oct 13, 2026 20:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001434647-26-000075 · wk-form4_1791923065.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. F4 · derivative.expiration_date: 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. Read SEC document |
| October 10, 2026 Filed Oct 13, 2026 20:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001434647-26-000075 · wk-form4_1791923065.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 437,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:49 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 14,625 | $8.56 | $125,185.61 |
DisclosureSEC source: 0001681098-26-000004 · wk-form4_1770760165.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,225 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/21/2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 21:49 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001681098-26-000004 · wk-form4_1770760165.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 21:49 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001681098-26-000004 · wk-form4_1770760165.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 22:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 91,000 | $9.38 | $853,425.30 |
DisclosureSEC source: 0001681098-26-000002 · wk-form4_1770070730.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 364,350 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-21-2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.94 to $9.53. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 233,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001681098-26-000002 · wk-form4_1770070730.xml · derivative · entry 5 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,333 Underlying: Common Stock · 233,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. F6 · derivative.expiration_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 233,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001681098-26-000002 · wk-form4_1770070730.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001681098-26-000002 · wk-form4_1770070730.xml · derivative · entry 4 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-01-28 F5 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001681098-26-000002 · wk-form4_1770070730.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 23:17 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001681098-25-000005 · wk-form4_1760138252.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. F3 · derivative.expiration_date: 25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 23:17 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 19,500 | $10.82 | $210,908.10 |
DisclosureSEC source: 0001681098-25-000005 · wk-form4_1760138252.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,016 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-21-2025. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 23:17 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001681098-25-000005 · wk-form4_1760138252.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 22:54 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 30,544 | $8.05 | $245,961.67 |
DisclosureSEC source: 0001437749-25-004067 · rdgdoc.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,516 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 10-15-2024 Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:54 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 61,273 | $7.86 | $481,428.09 |
DisclosureSEC source: 0001437749-25-004067 · rdgdoc.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,060 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 10-15-2024 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 22:37 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003328 · rdgdoc.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on February 7, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on February 7, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 22:37 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001437749-25-003328 · rdgdoc.xml · derivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 233,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002623 · rdgdoc.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,667 Underlying: Common Stock · 233,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F2 · derivative.expiration_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 233,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002623 · rdgdoc.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010541 · form4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,365 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 01:10 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003022 · rdgdoc.xml · derivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:33 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-028052 · rdgdoc.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F3 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units ("RSU") under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. F3 · derivative.expiration_date: Grant to the Reporting Person of restricted stock units ("RSU") under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:33 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001437749-23-028052 · rdgdoc.xml · derivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-10-09 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, October 10, 2023. F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:40 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011820 · form4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,672 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-013303 · form4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,880 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 21:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 17,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-010000 · form4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,845 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 6, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $1.99 | Not disclosed |
DisclosureSEC source: 0001328143-21-000093 · wf-form4_163778822454298.xml · derivative · entry 4 McFarlane Neil F. · CIK 0001681098 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-03-17 F8 · price: $6.11 plus two CVRs per share underlying the stock option. F5 · derivative.exercise_date: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001328143-21-000093 · wf-form4_163778822454298.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2029-09-15 F7 · price: $1.85 plus two CVRs per share underlying the stock option. F5 · derivative.exercise_date: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | OtherCommon Stock | 600,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001328143-21-000093 · wf-form4_163778822454298.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3 · shares: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F4 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001328143-21-000093 · wf-form4_163778822454298.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 F1 · shares: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 17:01 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016973 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 18:07 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-20-020527 · doc4.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-17 F2 · derivative.exercise_date: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 18:07 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020527 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of September 16, 2020, September 16, 2021, September 16, 2022 and September 16, 2023, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 19:00 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001209191-19-049941 · doc4.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-09-15 F2 · derivative.exercise_date: The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 19:00 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049941 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of September 16, 2020, September 16, 2021, September 16, 2022 and September 16, 2023, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 01:37 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 984 | $18.71 | $18,410.64 |
DisclosureSEC source: 0001209191-19-030661 · doc4.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,988 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 15, 2019 Filed May 17, 2019 01:37 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 984 | $17.78 | $17,495.52 |
DisclosureSEC source: 0001209191-19-030661 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,972 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.67 to $17.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:21 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 6,404 | $22.56 | $144,451.83 |
DisclosureSEC source: 0001209191-18-064023 · doc4.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,956 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.24 to $23.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:21 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 4,721 | $22.00 | $103,881.36 |
DisclosureSEC source: 0001209191-18-064023 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,360 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.76 to $22.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 00:57 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 11,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063774 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,081 F1 · kind: On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 22,250 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled. F2 · balance_after: Includes 480 shares of the Issuer's common stock acquired by the reporting person on November 30, 2018 pursuant to an employee stock purchase program. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,000 | $24.64 | $24,643.50 |
DisclosureSEC source: 0001209191-18-059067 · doc4.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,476 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 9,000 | $23.63 | $212,670.90 |
DisclosureSEC source: 0001209191-18-059067 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,476 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $24.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 09, 2018 Filed Nov 15, 2018 01:44 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058649 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,476 F1 · kind: On August 15, 2016, the reporting person was granted performance restricted stock units (PRSUs) covering 30,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner. F2 · balance_after: Includes 528 shares of the Issuer's common stock acquired by the reporting person on May 31, 2018 pursuant to an employee stock purchase program. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:33 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030057 · doc4.xml · derivative · entry 3 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:33 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 63,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030057 · doc4.xml · derivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:33 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030057 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,948 Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:38 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009398 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,448 F1 · balance_after: Includes 1,280 ordinary shares of the Issuer acquired by the reporting person on November 30, 2017 pursuant to an employee stock purchase program. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 00:36 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,378 | $22.50 | $31,005.00 |
DisclosureSEC source: 0001209191-17-049546 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,622 F1 · kind: Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:15 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033718 · doc4.xml · derivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal quarterly installments from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.